INS and type 2 diabetes mellitus: The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN Trials 1–5) phase 3 trials pooled analysis demonstrated the efficacy and safety of semaglutide 0.5 mg and 1 mg vs. comparators, which included placebo, sitagliptin, exenatide, or insulin in non‐older adults < 65 years and older adults > 65 years with T2DM.